Drug Search Results
More Filters [+]

Alizapride

Alternative Names: alizapride
Latest Update: 2021-09-01
Latest Update Note: PubMed Publication

Product Description

Dopamine D2 receptor antagonist with prokinetic and antiemetic effects which can also be used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11141)

Mechanisms of Action: DR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Belgium | Brazil | Colombia | Dominican Republic | Egypt | France | Italy | Luxembourg | Peru | Portugal | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Alizapride

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Oncology Solid Tumor Unspecified|Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

KMEC

P4

Completed

Oncology Solid Tumor Unspecified

2014-08-04

GEICAM/2009-02

P4

Completed

Breast Cancer

2013-03-01

Recent News Events